Last day of trading including subscription rights
(Oslo, Norway, 9 September 2016) Reference is made to the stock exchange announcement regarding the rights issue (the “Rights Issue”) of 525,000,000 new shares at a subscription price of NOK 0.10 per share in Bionor Pharma ASA (“Bionor” or the “Company”) dated 19 August 2016 and the separate announcement published today containing the resolution by the Company's extraordinary general meeting regarding the Rights Issue.
BIONOR PHARMA ASA
STOCK EXCHANGE ANNOUNCEMENT NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES
Shareholders of the Company as of the end of trading today, 9 September 2016 (registered as such in the Norwegian Central Securities Depository on 13 September 2016), will be granted transferable subscription rights in the Rights Issue, provided such shareholders are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Unni Hjelmaas, Acting CEO, +47 915 19 651, email@example.com
Jens Krøis, CFO, +45 2080 1668, firstname.lastname@example.org
Link to announcement in PDF